Because CCR3 is expressed in endothelial cells in the CNV membranes of eyes with dry AMD and has been used as an in vitro model of dry AMD, these findings suggest that CCR3 inhibition should be considered as a therapy for not only dry but also wet AMD through its protective effects on photoreceptor cells and the suppression of CNV. Here, CCR3 is linked to wet macular degeneration.